Danaher Co. (NYSE:DHR) Shares Sold by Plimoth Trust Co. LLC

Plimoth Trust Co. LLC cut its holdings in shares of Danaher Co. (NYSE:DHR) by 8.7% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,778 shares of the conglomerate’s stock after selling 170 shares during the period. Plimoth Trust Co. LLC’s holdings in Danaher were worth $444,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Tsfg LLC raised its stake in shares of Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after buying an additional 88 shares during the period. Cape Investment Advisory Inc. purchased a new position in Danaher during the fourth quarter valued at $25,000. BKM Wealth Management LLC acquired a new stake in shares of Danaher in the fourth quarter valued at about $27,000. Wetzel Investment Advisors Inc. purchased a new stake in shares of Danaher during the fourth quarter worth about $29,000. Finally, Rakuten Securities Inc. acquired a new position in shares of Danaher during the 4th quarter worth about $36,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on DHR shares. Bank of America lifted their price objective on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a report on Wednesday, April 24th. Barclays lifted their price target on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 24th. Jefferies Financial Group assumed coverage on Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective for the company. TD Cowen lifted their target price on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Finally, StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Six analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $268.67.

Insider Transactions at Danaher

In related news, Director Alan G. Spoon sold 708 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the sale, the director now directly owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, SVP Brian W. Ellis sold 4,000 shares of the stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total value of $1,000,040.00. Following the transaction, the senior vice president now owns 29,830 shares of the company’s stock, valued at $7,457,798.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Alan G. Spoon sold 708 shares of the company’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the transaction, the director now directly owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 148,783 shares of company stock valued at $37,536,717. 10.90% of the stock is currently owned by corporate insiders.

Danaher Price Performance

Danaher stock opened at $240.21 on Thursday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. The company has a market capitalization of $177.92 billion, a price-to-earnings ratio of 40.71, a price-to-earnings-growth ratio of 3.82 and a beta of 0.84. The company’s 50 day simple moving average is $255.88 and its 200-day simple moving average is $246.95. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $269.11.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The company had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. During the same period in the prior year, the firm earned $2.36 earnings per share. The firm’s revenue was down 2.6% compared to the same quarter last year. As a group, equities research analysts expect that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be paid a dividend of $0.27 per share. The ex-dividend date is Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.